Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Inclusion criteria: * Male or female patients aged ≥ 18 years old * Diagnosis of Philadelphia chromosome positive accelerated or blast phase chronic myeloid leukemia defined as: Accelerated phase - the presence of at least one of the following: * ≥15% but \<30% blasts in blood or bone marrow * ≥30% blasts plus promyelocytes in peripheral blood or bone marrow (providing that \<30% blasts present in bone marrow) * ≥ 20% basophiles in the peripheral blood * Thrombocytopenia \<100 X 109 /L unrelated to sole therapy Blast phase (blast crisis) - the presence of one of the following: * ≥ 30% blasts in the blood, in bone marrow or both * Extramedullary infiltrates of leukemic cells other than liver or spleen involvement * Prior treatment with at least two a fusion gene of the BCR and ABL genes (BCR-ABL) tyrosine kinase inhibitors (i.e., imatinib, nilotinib, or dasatinib) and demonstrated resistance to the most recent kinase inhibitor therapy. Resistance to a BCR-ABL tyrosine kinase inhibitors (TKI) for this study was defined as: * Progression from chronic phase to either accelerated phase or blast crisis * Progression from accelerated phase to blast crisis * No hematologic response (defined as not achieving complete hematologic response (CHR), no evidence of leukemia (NEL) or return to chronic phase (RTC)) within 3 months of starting therapy * Increasing blast counts in peripheral blood of increasing marrow leukemic infiltrate (MLI, the percent marrow blasts multiplied …